Anti-Remicade antibodies also cross-react with infliximab biosimilarMarch 14, 2016Psoriatic Arthritis
60 weeks of ixekizumab effective, well tolerated in moderate-to-severe plaque psoriasisMarch 10, 2016Psoriatic Arthritis
Subclinical inflammation predicts progression from psoriasis to PsAFebruary 29, 2016Psoriatic Arthritis
